Domiciliary Positive Expiratory Pressure Improves Pulmonary Function and Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease  by Su, Chien-Ling et al.
204 J Formos Med Assoc | 2007 • Vol 106 • No 3
ORIGINAL ARTICLE
Chronic obstructive pulmonary disease (COPD)
is a major and increasing global health problem
that has become a leading cause of fatality.1
COPD has multiple components which, in addi-
tion to a systemic component, include pulmonary
inflammation, airway remodeling and mucociliary
dysfunction. These latter features contribute to
development of chronic, progressive airflow lim-
itation. The mucociliary dysfunction component
of COPD is caused by mucus hypersecretion com-
bined with decreased mucus transport, and are
important pathophysiologic features that require
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(6MWD) also increased significantly from 516.8 ± 94.1 to 570.6 ± 60.4 m in the PEP + FET group (p < 0.001)
after intervention, compared to that for the FET group (p < 0.05). Additionally, the PEP + FET group had
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prompt treatment.2 Mucus hypersecretion results
from autonomic nerve dysfunction and various
chemical mediators, resulting in airflow limita-
tion.3 In COPD, considerable controversy exists
regarding the importance of mucus hypersecretion.
Long-term mucus impaction in small airways
causes ventilation/perfusion mismatch, pulmonary
hyperinflation, increased work while breathing,
and exercise intolerance. Thus, airway mucus clear-
ance is essential for COPD patients and should be
optimized with appropriate therapeutic interven-
tion. Although airway clearance modalities have
been widely utilized in cystic fibrosis4–6 and
bronchiectasis,7 few studies have focused on COPD
patients with mucus hypersecretion.
The forced expiratory technique (FET) is a form
of chest physiotherapy that can be self-adminis-
tered to enhance mucus clearance from the airways
of cystic fibrosis patients.6 During FET, huffing is
combined with postural drainage, breathing exer-
cises and, when necessary, coughing to encourage
mucus clearance from peripheral airways to central
airways and easy expectoration of sputum. The
FET can be self-administered without assistance.
Therefore, FET has been proposed as an effective
method for home physiotherapy for patients with
chronic inflammatory airway diseases such as
cystic fibrosis and bronchiectasis.8 However, FET
can induce early closure of airways, thus leading
to bronchoconstriction and impairment of cough
function.9 Moreover, flattening the diaphragm in
COPD patients combined with lung hyperinfla-
tion frequently results in inefficient diaphrag-
matic breathing during FET. Therefore, maneuvers
to prevent airway closure and lung hyperinfla-
tion during FET alone can increase the efficacy of
FET in clearing mucus from the airways of COPD
patients.
In 1984, Falk et al10 developed the positive ex-
piratory pressure (PEP) mask technique for the
removal of airway secretions. The clinical and
physiologic utility of PEP has been accepted in
recent years.11 Previous studies have demonstrated
that the PEP mask is at least as effective as conven-
tional postural drainage and percussion in mobi-
lizing secretions in patients with cystic fibrosis.12
McIlwaine et al13 also demonstrated that PEP has
a better long-term effect on pulmonary function
than flutters. The pressure generated by applying
PEP therapy distal to an obstruction through col-
lateral pathways may enhance FET efficacy in
promoting movement of secretions toward large
airways14 and reduced pulmonary hyperinflation
and airway instability15,16 in patients with COPD
and mucus hypersecretion. Thus, we hypothesize
that PEP as an adjunct to FET is more efficient than
FET only.
This study evaluated the effects of modified
PEP techniques combined with FET in COPD 
patients with mucus hypersecretion in terms of
pulmonary function, exercise tolerance, and sub-
jective expectoration difficulty scores after 4 weeks
of treatment. This study also investigated the 
relationship between pulmonary function and




Thirty-seven ambulatory outpatients with COPD
who met the diagnostic criteria of the American
Thoracic Society (ATS)17 were recruited from July
1999 to July 2000. All enrolled subjects met the
following criteria: (1) under regular medication
treatment and clinically stable, i.e. without acute
asthmatic attacks or airway infections in the 2
months prior to the study; (2) producing at least
25 cc of sputum in 24 hours; (3) able and willing
to self-administer treatment daily; and (4) coopera-
tive and motivated, with good medication compli-
ance and willing to attend regular follow-up at
an outpatient clinic for 3 months. Subjects who
met one of the following criteria were excluded:
(1) have other major diseases, such as heart dis-
ease, orthopedic, and/or neurologic problems;
(2) poor compliance with medications and/or
home bronchial hygiene program; (3) requiring
oxygen and/or continuous positive airway pres-
sure therapy at home; and (4) on a regular chest
physiotherapy program. 
Study subjects were randomly divided into
two groups: (1) PEP adjunct to FET (PEP + FET)
group; (2) FET only (FET) group. All enrolled
subjects were numbered by a computer-generated
randomized method. Thirty-seven patients were
initially enrolled in this study. Five patients were
dropped out of the study: two had poor compli-
ance (one in each group), and two in the PEP
group and one in the FET group deteriorated dur-
ing the study period. Therefore, 32 subjects (n = 16
in each group) finished the 4-week intervention
program. The protocol was approved by the Ethics
Committee at Chung Gung Memorial Hospital
and informed consent was obtained from each
subject prior to participation.
Interventions
FET
This method consisted of forced expirations from
mid-lung volume to low-lung volume followed
by a short period of relaxation and breathing con-
trol.18 Each cycle of FET comprised six forced ex-
pirations with a short period of relaxation after
three expirations. The sequence of deep breathing
and six forced expirations was repeated six times
while in a sitting position. 
PEP and FET
The PEP system (Thera PEP; DHD Healthcare
Co., NY, USA) consists of a mouthpiece and a
one-way valve to which expiratory resistance
(orifice) is attached. An expiratory airway pres-
sure indicator is inserted into the system to visu-
ally confirm pressure range of 10–20cmH2O.19
Resistance was adjusted so that the patient was
expiring against a pressure of 10–20 cm H2O,
reaching an inspiration-to-expiration ratio of 1:3
to 1:4, or longer. One minute of PEP breathing in
the sitting position was followed by forced expi-
rations and a short period of relaxation and con-
trolled breathing. Each session had 10 cycles of
PEP breathing. The number of forced expirations
in the two regimens was thus identical. The pres-
sure level of PEP was individualized and adjusted
according to the patient’s condition during the
study period.
Subjects performed the treatment program at
home twice daily, once in the early morning and
once at night before sleep for 4 weeks. All pa-
tients were requested to perform the techniques
properly under the supervision of physical thera-
pists on the first 3 study days. Subjects were con-
tacted by phone every 3 days to confirm their
adherence to the program and their (PEP and
FET) techniques were rechecked at an outpatient
clinic weekly.
Measurements
Pulmonary function tests, 6-minute walk tests
(6MWT), and cough difficulty scores (CDS) were
assessed before and after the 4-week period. The
technicians and physicians in this study were blind
to the treatment regimen. Subjects maintained
their regular medication regimen and dosage but
refrained from using short-acting bronchodila-
tors for 8 hours, long-acting bronchodilators for
24 hours, and smoking for 8 hours before all tests.
All subjects were asked not to drink coffee or tea
on the mornings of the test days.
Pulmonary function tests
Pulmonary function tests were performed accord-
ing to ATS guidelines.17 The pulmonary functions
(PFs), including forced vital capacity (FVC), forced
expiratory volume in 1 second (FEV1), forced ex-
piratory flow from 25% to 75% (FEF25–75%), peak
expiratory flow (PEF), residual volume (RV), total
lung capacity (TLC), functional residual capacity
(FRC), and diffusing capacity (DLCO) were meas-
ured by plethysmography (Sensor Medics, CA,
USA). DLCO was examined by a single breath
method with a single carbon monoxide sample
obtained after the subject held their breath for 
10 seconds. Three trials were performed, and the
best trial was recorded. Volume measurement 
accuracy was set at less than ± 3% deviation with 
a 3L calibration syringe; a leaking test was per-
formed daily.20 The gas analyzer linearity and
timer were also tested and had less than 1% devi-
ation.21 Reproducibility of two acceptable tests
was within 0.2 L in volume measurements and
within 10% in DLCO measurements.
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6MWT
To minimize the learning effect during the walk-
ing test, all subjects were asked to practice the
6MWT 1 week prior to the study. The 6MWT was
performed in accordance with the ATS State-
ment.22 All subjects completed two 6MWTs and
the farthest of the two walking distances (WD)
was utilized for analysis. The modified Borg 
scale was evaluated at rest and immediately after
exercise, and expressed as RBorg and EBorg, re-
spectively.23 During walking tests, subjects were
monitored with a continuous pulse oximeter
(3301; BCI International Co., WI, USA). Oxygen
saturation (O2SAT) was recorded and printed
every 6 seconds at rest (RO2SAT) and during ex-
ercise (EO2SAT), as determined by pulse oximetry.
The intrarater reliability of the 6MWT and modi-
fied Borg scale were examined for 15 patients with
chronic obstructive lung disease (FEV1 48.2 ± 3.6%
predicted) on 2 consecutive days. Intraclass cor-
relation coefficients (ICC) of 0.99 (95% confi-
dence interval [CI], 0.98–0.99; p < 0.001) in WD,
0.89 (95% CI, 0.71–0.96; p < 0.001) in RBorg,
and 0.58 (95% CI, 0.12–0.84; p < 0.01) in EBorg
were obtained.
Cough difficulty assessment
A subjective assessment of “the degree of cough
difficulty score” was determined using a scale with
the following five fixed points: 1 point, “very easy”;
2 points, “easy”; 3 points, “no change”; 4 points,
“with difficulty”; and, 5 points, “very difficult.”
In this study, the ICC of intrarater reliability of
CDS for 14 COPD patients was 0.95 (95% CI,
0.85–0.98; p < 0.001).
Data analysis
Data were analyzed using commercially available
software (SYSTAT 10.0; SPSS Inc., Chicago, IL,
USA). Mann-Whitney U tests were used to detect
significant differences in basic characteristics and
baseline data for each intervention (i.e. PFs,
6MWTs, and CDS). To examine the effects of the
interventions on PFs, 6MWTs, and CDS, Wilcoxon
matched pair tests were used to test for significant
differences between baseline and postintervention
data within groups, and the Mann-Whitney U
tests were utilized for postintervention data be-
tween groups. The level of significance was set 
at 0.05.
Results
No significant differences existed between the two
groups for age, gender, height, weight, and PFs.
Mean age was 59.1 ± 11.6 years in the PEP + FET
group and 64.6 ± 9.5 years in the FET group. Mean
FEV1 was 48.1 ± 15.5% and 52.9 ± 16.7% of pre-
dicted values in the PEP + FET group and FET
group, respectively (Table 1).
Baseline parameters
No statistically significant differences existed be-
tween baseline data for PFs (FVC, FEV1, FEF25–75%,
PEF, RV, TLC, FRC, and DLCO) (Table 2), 6MWTs
Table 1. Characteristics of patients with chronic obstructive pulmonary disease in the PEP+FET and FET groups*
PEP + FET (n = 16) FET (n = 16) p
Age (yr) 59.1 ± 11.6 (26–75) 64.6 ± 9.5 (40–79) 0.148
Male/female (n) 13/3 12/4 0.975
Height (m) 1.63 ± 7.4 (1.47–1.75) 1.59 ± 9.0 (1.41–1.73) 0.439
Weight (kg) 66.3 ± 10.5 (50–82) 62.8 ± 12.1 (44–84) 0.440
FVC (% predicted) 68.8 ± 15.5 (44–92) 70.1 ± 17.9 (43–98) 0.801
FEV1 (% predicted) 48.1 ± 15.5 (22–74) 52.9 ± 16.7 (27–69) 0.392
FEV1/FVC (%) 55.0 ± 11.3 (41–76) 58.6 ± 9.0 (44–77) 0.283
*Data are presented as mean ± standard deviation (range). PEP = positive expiratory pressure; FET = forced expiratory technique; 
FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second; FEV1/FVC = ratio of FEV1 to FVC.
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(6MWD, RBorg, EBorg, RO2SAT, EO2SAT) (Table 3)
and CDS.
Effects of PEP on PFs
FVC, FEV1, FEF25–75%, and PEF significantly in-
creased in the PEP + FET group from 2.2 ± 0.8 
to 2.4 ± 0.9 L (p < 0.001), 1.2 ± 0.5 to 1.4 ± 0.6 L/
second (p<0.001), 0.7±0.4 to 0.8±0.4L/second
(p<0.05), and 3.4 ± 1.2 to 4.1 ± 1.5 L/second, re-
spectively (Table 2). FVC in the FET group also
significantly increased from 1.9 ± 0.6 to 2.1 ± 0.6 L
(p < 0.05), and the RV and FRC decreased from
3.8 ± 0.9 to 3.3 ± 0.9 L (p < 0.01), and 4.1 ± 1.0 to
3.7 ± 1.0 (p < 0.05), respectively. However, the
difference between groups for PF parameters was
not significantly different.
DLCO improved significantly in the PEP +
FET group from 18.0 ± 7.3 to 20.1 ± 7.2 mL/min/
mmHg (p < 0.05). Additionally, PEP + FET was
more effective than FET alone in reducing DLCO
(p < 0.05).
Effects of PEP on 6MWT
The 6MWD increased from 516.8 ± 94.1 to
570.6 ± 60.4 m in the PEP group (p < 0.001), and
from 498.8 ± 61.8 to 526.4 ± 57.7 m in the FET
group (p < 0.01); furthermore, PEP + FET was more
effective than FET alone in increasing 6MWD
(p < 0.05). Table 3 presents the Borg scores dur-
ing the 6MWTs before and after treatments.
There was a significant decrease in subjective
Borg breathlessness sensation at rest (p < 0.05)
and at the end of the 6MWT (p < 0.01) in both
groups. However, the differences in Borg scores
between the two groups did not reach statisti-
cal significance. No significant difference existed
Table 2. Changes to pulmonary functions in the PEP + FET and FET groups*
PEP + FET FET
Baseline data Posttreatment Baseline data Posttreatment
FVC (L) 2.2 ± 0.8 (1.2–4.6) 2.4 ± 0.9† (1.2–5.1) 1.9 ± 0.6 (1.1–3.2) 2.1 ± 0.6‡ (1.2–3.3)
FEV1 (L) 1.2 ± 0.5 (0.5–2.4) 1.4 ± 0.6† (0.6–3.0) 1.2 ± 0.4 (0.7–2.1) 1.2 ± 0.4 (0.7–2.0)
FEF25–75% (L/sec) 0.7 ± 0.4 (0.2–1.4) 0.8 ± 0.4‡ (0.3–1.9) 0.7 ± 0.3 (0.3–1.2) 0.7 ± 0.3 (0.3–1.3)
PEF (L/sec) 3.4 ± 1.2 (1.4–5.5) 4.1 ± 1.5§ (2.1–7.8) 3.4 ± 1.6 (1.6–7.3) 3.8 ± 1.3 (1.7–6.4)
TLC (L) 6.6 ± 1.7 (4.5–10.9) 6.3 ± 1.0 (4.6–7.7) 6.0 ± 1.1 (3.8–7.8) 5.7 ± 1.2 (3.5–7.8)
RV (L) 4.3 ± 1.6 (2.6–9.0) 3.8 ± 1.0 (2.4–5.4) 3.8 ± 0.9 (2.1–5.3) 3.3 ± 0.9§ (1.8–4.7)
FRC (L) 4.5 ± 1.5 (2.6–8.8) 4.4 ± 1.0 (2.7–6.3) 4.1 ± 1.0 (2.1–5.7) 3.7 ± 1.0‡ (2.1–5.3)
DLCO (mL/min/mmHg) 18.0 ± 7.3 (6.3–35.5) 20.1 ± 7.2‡|| (6.0–35.3) 16.4 ± 5.5 (6.7–27.3) 16.0 ± 4.0 (8.8–25.1)
*Data are presented as mean ± standard deviation (range); †p<0.001 vs. baseline; ‡p<0.05 vs. baseline; §p<0.01 vs. baseline; ||p < 0.05
vs. FET group. PEP = positive expiratory pressure; FET = forced expiratory technique; FVC = forced vital capacity; FEV1 = forced expiratory
volume in 1 second; FEF25–75% = forced expiratory flow in 25–75% forced expiratory volume; PEF = peak expiratory flow; TLC= total lung
capacity; RV = residual volume; FRC = functional residual capacity; DLCO = diffusion capacity.
Table 3. Changes during the 6-minute walk test in the PEP + FET and FET groups*
PEP + FET FET
Baseline data Posttreatment Baseline data Posttreatment
6MWD (m) 516.8±94.1 (320–640) 570.6±60.4†‡ (450–667) 498.8±61.8 (332–609) 526.4±57.7§ (406–638)
RBorg 2.3 ± 0.7 (1–4) 1.8 ± 0.4|| (1–2) 2.2 ± 1.0 (1–4) 1.8 ± 0.7|| (0.5–3)
EBorg 5.1 ± 1.1 (4–7) 4.2 ± 1.0§ (3–7) 4.8 ± 1.2 (3–7) 4.1 ± 1.3§ (3–7)
RO2SAT (%) 95.7 ± 1.5 (92–97) 96.3 ± 1.1 (93–97) 95.7 ± 1.2 (93–98) 96.1 ± 1.3 (93–98)
EO2SAT (%) 88.9 ± 7.7 (66–97) 90.6 ± 7.2 (70–98) 91.1 ± 5.4 (80–97) 91.4 ± 5.0 (82–97)
*Data are presented as mean± standard deviation (range); †p < 0.001 vs. baseline; ‡p < 0.05 vs. FET; §p < 0.01 vs. baseline; ||p < 0.05 vs.
baseline. PEP = positive expiratory pressure; FET = forced expiratory technique; 6MWD = 6-minute walking distance; RBorg = Borg score
at rest; EBorg = Borg score at end of exercise; RO2SAT = oxygen saturation at rest; EO2SAT = oxygen saturation at end of exercise.
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for O2SAT during 6MWT within and between
groups.
Effects of PEP on CDS
Patients in both groups had reduced CDS (Figure).
Additionally, statistical analyses detected a signifi-
cant difference in postintervention CDS between
groups (3.3 ± 0.7 and 2.3 ± 0.6 in PEP + FET and
FET groups, individually, p < 0.01).
Discussion
Mucus hypersecretion with viscid mucus plugs 
in the airway of COPD patients contributes to
respiratory insufficiency. Good airway hygiene 
is essential to COPD management. This study
demonstrated that 4-week regimens of regular
physiotherapy, either PEP + FET or FET alone, im-
proves FVC, WD, subjective breathlessness sensa-
tion, and CDS in COPD patients with mucus
hypersecretion. Application of external PEP signif-
icantly improved the clinical efficacy of FET for
long-term treatment of COPD by improving PFs,
including FEV1, FEF25–75%, PEF, DLCO, and spu-
tum expectoration difficulty.
Ventilatory limitations in COPD patients are
caused by airway inflammation that generates
bronchospasms, airway hyperresponsiveness, and
mucus hypersecretion. Mucus in the airways ag-
gravates airway hyperresponsiveness in COPD
patients1 and lung atelectasis. Medical treatment,
including anti-inflammatory agents, attenuates air-
way inflammation but does not eliminate airway
hyperresponsivenesss. The instability of airways
leads to early closure of the small airways and air
becoming trapped in the lungs. In patients with
mucus hypersecretion, early closure of the small
airways can further hamper clearing of airway
mucus. Therefore, facilitating mucus clearance is an
essential part of maintenance treatment in COPD
patients with mucus hypersecretion. Furthermore
mucus clearance increases effective ventilation and
reduces airway hyperresponsiveness. However,
maintenance of airway stability is promising for
effective mucociliary clearance in small airway
diseases.15 This study demonstrated that FET 
improves ventilation volume, air trapping, exer-
cise tolerance and subjective dyspnea sensation.
However, as advanced stages of COPD are char-
acterized by airway instability, the effectiveness
of FET may be hampered by airway collapse.4
Applying PEP therapy via the mouth to COPD
patients can prevent airway closure during forced
expiration in FET. Additionally, PEP allows in-
creased amounts of air to enter through collateral
channels, facilitating reinflation of collapsed
alveoli.14,24,25 Moreover, Laube et al26 concluded
that aerosol administration with nebulizer and
PEP device also results in a proportional redistri-
bution of aerosol to the peripheral airway, com-
pared with nebulizeration without the PEP device,
Figure. (A) Improvement in sputum expectoration difficulty (cough difficulty) in the PEP + FET and FET groups. 
(B) Magnitude of change in cough difficulty in the PEP + FET and FET groups. Results are presented as mean ± standard
error of the mean. PEP = positive expiratory pressure; FET = forced expiratory technique. *p < 0.001; †p < 0.01.
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suggesting that PEP + FET can enhance the con-
trol of COPD by improving the efficiency of
aerosolized medications. Therefore, PEP + FET may
recruit additional collapsed alveoli thereby aug-
menting the match ratio of ventilation-perfusion
and leading to increased DLCO,27 as demon-
strated in this study.
Previous studies have described the effects of
PEP mask physiotherapy on lung function in cys-
tic fibrosis, but not in COPD.27–29 Christensen
et al28 showed that 9-month PEP physiotherapy
enhances FEV1 in cystic fibrosis. Oberwaldner 
et al15 proposed that PEP therapy for 6 months
improved FVC, FEV1, FEF25–75%, FEF, and RV/TLC
in patients with cystic fibrosis. McIlwaine et al12
also provided evidence that FVC and FEV1 im-
proved after 1-year PEP mask treatment in patients
with cystic fibrosis compared with that obtained
using conventional physiotherapy. Steen et al29
and Kaminska et al30 suggested that 4-week PEP
mask treatment combined with FET is an effec-
tive treatment that increased independence in
daily activities. As the same combination therapy
was used in this study, it is reasonable to select 4
weeks as the treatment period. This study further
confirmed the effect of a 4-week regimen of com-
bination therapy with modified PEP and FET on
increasing DLCO and exercise distance in the two
study groups. A longer follow-up period than
that in this study is required.
High-pressure PEP masks may mechanically
irritate intrathoracic airways, thereby resulting in
bronchospasms in patients with airway hyperre-
activity.4,31 Furthermore, the discomfort from wear-
ing a fitted mask results in poor treatment
compliance. The PEP system utilized in this
study generates an expiratory airway pressure of
10–20 cmH2O19 in the airways via a mouthpiece
and one-way valve. Therefore, PEP reduces dis-
comfort and increases expectoration. This PEP
system was well accepted and resulted in com-
plete compliance by patients.
The study sample size was small, with only
16 subjects in each group for 32 data sets.
Furthermore, nonsignificant differences for most
PFs and Borg’s scale, and O2SAT between groups
during exercise may be associated with type II 
errors due to the small sample size. Therefore, this
study should be regarded as a pilot study.
The study design was another limitation. The
4-week intervention in this study is shorter than
the 1-year studies by McIlwaine et al12,13 and
Christensen et al.28 Despite some positive obser-
vations, results from this study must be replicated
for a longer period. The method had another lim-
itation. Measurements of RV, TLC and FRC in the
body plethysmography by painting maneuvers
were technically difficult for most of the COPD
patients with mucus hypersecretion.
This study demonstrated that PEP as an ad-
junct to FET is more effective than FET only in
improving DLCO, 6MWD, and reducing sputum
expectoration difficulty in COPD patients with
mucus hypersecretion. Therefore, PEP + FET ther-
apy is a noninvasive, inexpensive, and non-time-
consuming domiciliary intervention. 
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